[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_eiTEoH4uUHbkrKRr-Ujll0W-06Ke_fmO4q0QhqQsjw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Université Catholique de Louvain",[4],142,false,45,1,32622,129,[13,16,19,22,24,27,29,31],{"name":14,"count":15},"Healthy",13,{"name":17,"count":18},"Cerebral Palsy",11,{"name":20,"count":21},"Rheumatoid Arthritis",4,{"name":23,"count":21},"Stroke",{"name":25,"count":26},"Depression",3,{"name":28,"count":26},"Low Back Pain",{"name":30,"count":26},"Parkinson Disease",{"name":32,"count":26},"Cachexia",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07384910","Assessment of GARP Expression in Acute and Chronic Coronary Syndrome","2028-01","Arterial blood sample",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,70,97,115,133,151,178,203,229,254,283,301,327,354,381,406,437,455,473],{"intervention":38,"totalTrials":9,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":60},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":51},[],{"trials":61,"activeCount":9,"soonestReadout":37},[62],{"nctId":35,"briefTitle":36,"status":63,"phases":64,"primaryCompletion":37,"completion":37,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NOT_YET_RECRUITING",[45],"2026-02",600,[68],"Atheroma; Heart",[38],{"intervention":71,"totalTrials":9,"cells":72},"Infliximab, methylprednisolone, methotrexate",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":95},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"completion":88,"start":89,"enrollment":8,"conditions":90,"interventions":91},"NCT00396747","A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study","COMPLETED",[44],"2005-09","2003-06",[20],[71,92,93,94],"Methotrexate","Methotrexate + Methylprednisolone","Methotrexate + Infliximab",{"trials":96,"activeCount":51},[],{"intervention":92,"totalTrials":9,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":113},{"trials":100,"activeCount":51},[],{"trials":102,"activeCount":51},[],{"trials":104,"activeCount":51},[],{"trials":106,"activeCount":51},[],{"trials":108,"activeCount":51},[109],{"nctId":84,"briefTitle":85,"status":86,"phases":110,"completion":88,"start":89,"enrollment":8,"conditions":111,"interventions":112},[44],[20],[71,92,93,94],{"trials":114,"activeCount":51},[],{"intervention":93,"totalTrials":9,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":131},{"trials":118,"activeCount":51},[],{"trials":120,"activeCount":51},[],{"trials":122,"activeCount":51},[],{"trials":124,"activeCount":51},[],{"trials":126,"activeCount":51},[127],{"nctId":84,"briefTitle":85,"status":86,"phases":128,"completion":88,"start":89,"enrollment":8,"conditions":129,"interventions":130},[44],[20],[71,92,93,94],{"trials":132,"activeCount":51},[],{"intervention":94,"totalTrials":9,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":149},{"trials":136,"activeCount":51},[],{"trials":138,"activeCount":51},[],{"trials":140,"activeCount":51},[],{"trials":142,"activeCount":51},[],{"trials":144,"activeCount":51},[145],{"nctId":84,"briefTitle":85,"status":86,"phases":146,"completion":88,"start":89,"enrollment":8,"conditions":147,"interventions":148},[44],[20],[71,92,93,94],{"trials":150,"activeCount":51},[],{"intervention":152,"totalTrials":9,"cells":153},"Advagraf",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":176},{"trials":155,"activeCount":51},[],{"trials":157,"activeCount":51},[],{"trials":159,"activeCount":51},[],{"trials":161,"activeCount":51},[],{"trials":163,"activeCount":51},[164],{"nctId":165,"briefTitle":166,"status":167,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT02311010","Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism","UNKNOWN",[44],"2014-10","2015-01","2011-01",150,[174],"Kidney Diseases",[152],{"trials":177,"activeCount":51},[],{"intervention":179,"totalTrials":9,"cells":180},"Atorvastatin",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":201},{"trials":182,"activeCount":51},[],{"trials":184,"activeCount":51},[],{"trials":186,"activeCount":51},[],{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[191],{"nctId":192,"briefTitle":193,"status":86,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT03604471","Lipid-lowering Therapy Individualization",[44],"2019-08-27","2017-08-08",75,[199],"Hypercholesterolemia",[179],{"trials":202,"activeCount":51},[],{"intervention":204,"totalTrials":9,"cells":205},"Temocillin",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":227},{"trials":207,"activeCount":51},[],{"trials":209,"activeCount":51},[],{"trials":211,"activeCount":51},[],{"trials":213,"activeCount":51},[],{"trials":215,"activeCount":51},[216],{"nctId":217,"briefTitle":218,"status":167,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":8,"conditions":222,"interventions":226},"NCT02260102","Temocillin Pharmacokinetics in Paediatrics",[44],"2022-12-31","2016-02-17",[223,224,225],"Infection","Liver Dysfunction","Urinary Tract Infection",[204],{"trials":228,"activeCount":51},[],{"intervention":230,"totalTrials":9,"cells":231},"Darunavir",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":252},{"trials":233,"activeCount":51},[],{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[],{"trials":241,"activeCount":51},[242],{"nctId":243,"briefTitle":244,"status":86,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT03101644","Optimization of Darunavir Therapy and Dosage Recommendations",[44],"2019-06-12","2017-03-23",127,[250],"Human Immunodeficiency Virus I Infection",[230],{"trials":253,"activeCount":51},[],{"intervention":255,"totalTrials":9,"cells":256},"Ketorolac 30 mg IV",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":279,"NA":281},{"trials":258,"activeCount":51},[],{"trials":260,"activeCount":51},[],{"trials":262,"activeCount":51},[],{"trials":264,"activeCount":51},[265],{"nctId":266,"briefTitle":267,"status":86,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":277},"NCT01806259","Ketorolac in Breast Cancer Surgery",[43],"2015-10","2018-09","2013-02",203,[274,275,276],"Curative Breast Cancer Surgery","Inflammatory Positive\u002FNegative Status","Pre Surgical Incision Administration",[255,278],"Placebos",{"trials":280,"activeCount":51},[],{"trials":282,"activeCount":51},[],{"intervention":278,"totalTrials":9,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":297,"NA":299},{"trials":286,"activeCount":51},[],{"trials":288,"activeCount":51},[],{"trials":290,"activeCount":51},[],{"trials":292,"activeCount":51},[293],{"nctId":266,"briefTitle":267,"status":86,"phases":294,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":295,"interventions":296},[43],[274,275,276],[255,278],{"trials":298,"activeCount":51},[],{"trials":300,"activeCount":51},[],{"intervention":302,"totalTrials":9,"cells":303},"oral salmon calcitonin",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":305,"activeCount":51},[],{"trials":307,"activeCount":51},[],{"trials":309,"activeCount":51},[310],{"nctId":311,"briefTitle":312,"status":313,"phases":314,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT00376311","Effects of Oral Salmon Calcitonin in Human Osteoarthritis","TERMINATED",[42],"2004-05","2002-09",54,[319],"Osteoarthritis",[302],{"trials":322,"activeCount":51},[],{"trials":324,"activeCount":51},[],{"trials":326,"activeCount":51},[],{"intervention":328,"totalTrials":9,"cells":329},"Tacrolimus",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[],{"trials":337,"activeCount":51},[],{"trials":339,"activeCount":51},[],{"trials":341,"activeCount":51},[342],{"nctId":343,"briefTitle":344,"status":167,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":353},"NCT04360031","The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation",[],"2021-03","2020-02-10",100,[350,351,352],"Kidney Transplant; Complications","Immunosuppression","Transplant Failure",[328],{"intervention":355,"totalTrials":9,"cells":356},"Opioid drug + CNS-acting add-on drug",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[],{"trials":362,"activeCount":51},[],{"trials":364,"activeCount":51},[],{"trials":366,"activeCount":51},[],{"trials":368,"activeCount":51},[369],{"nctId":370,"briefTitle":371,"status":167,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":172,"conditions":375,"interventions":380},"NCT06244706","QSPainRelief-STRAT",[45],"2025-12-31","2024-02-01",[376,377,378,379],"Chronic Pain","Analgesia","Adverse Drug Event","Drug Interaction",[355],{"intervention":382,"totalTrials":9,"cells":383},"Bisphosphonate treatment",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":385,"activeCount":51},[],{"trials":387,"activeCount":51},[],{"trials":389,"activeCount":51},[],{"trials":391,"activeCount":51},[],{"trials":393,"activeCount":51},[],{"trials":395,"activeCount":51},[396],{"nctId":397,"briefTitle":398,"status":86,"phases":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},"NCT00306046","18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone",[45],"2006-03","2002-02",20,[404],"Paget's Disease of Bone",[382],{"intervention":407,"totalTrials":9,"cells":408},"blood sampling",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":410,"activeCount":51},[],{"trials":412,"activeCount":51},[],{"trials":414,"activeCount":51},[],{"trials":416,"activeCount":51},[],{"trials":418,"activeCount":51},[],{"trials":420,"activeCount":51},[421],{"nctId":422,"briefTitle":423,"status":167,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":402,"conditions":428,"interventions":434},"NCT03440216","Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units",[45],"2022-10-15","2022-12-15","2018-03-15",[429,430,431,432,223,433],"Pharmacokinetics","Anti-Bacterial Agents","Infection, Bacterial","Infections, Respiratory","Drug Monitoring",[407,435,436],"Tissue sampling","Collection of fluid samples",{"intervention":435,"totalTrials":9,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":440,"activeCount":51},[],{"trials":442,"activeCount":51},[],{"trials":444,"activeCount":51},[],{"trials":446,"activeCount":51},[],{"trials":448,"activeCount":51},[],{"trials":450,"activeCount":51},[451],{"nctId":422,"briefTitle":423,"status":167,"phases":452,"primaryCompletion":425,"completion":426,"start":427,"enrollment":402,"conditions":453,"interventions":454},[45],[429,430,431,432,223,433],[407,435,436],{"intervention":436,"totalTrials":9,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":458,"activeCount":51},[],{"trials":460,"activeCount":51},[],{"trials":462,"activeCount":51},[],{"trials":464,"activeCount":51},[],{"trials":466,"activeCount":51},[],{"trials":468,"activeCount":51},[469],{"nctId":422,"briefTitle":423,"status":167,"phases":470,"primaryCompletion":425,"completion":426,"start":427,"enrollment":402,"conditions":471,"interventions":472},[45],[429,430,431,432,223,433],[407,435,436],{"intervention":474,"totalTrials":9,"cells":475},"Mody test",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":477,"activeCount":51},[],{"trials":479,"activeCount":51},[],{"trials":481,"activeCount":51},[],{"trials":483,"activeCount":51},[],{"trials":485,"activeCount":51},[],{"trials":487,"activeCount":51},[488],{"nctId":489,"briefTitle":490,"status":86,"phases":491,"primaryCompletion":492,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":499},"NCT04021199","Screening for Genetic Forms of Diabetes in Convention of Care for Children and Adolescents With Diabetes (GENEPEDIAB)",[45],"2021-10-22","2022-06-22","2018-10-22",446,[497,498],"Diabetes Mellitus","MODY",[474]]